WebDoctor Encyclopedia

Article

Brachytherapy (Internal Radiotherapy)

What is brachytherapy?

Brachytherapy is a type of internal radiotherapy. Instead of aiming radiation at the body from a machine outside, a radioactive source is placed inside or right next to the tumour. Its name is taken from brachys, an ancient Greek term for “short”, since the radiation reaches only a little way into the surrounding tissue.

Because the source sits so close to the cancer, brachytherapy can give a very high dose to the tumour while the dose falls away quickly in the surrounding healthy tissue. This makes it one of the most precise forms of radiotherapy available.

Brachytherapy is used most often for cancers of the cervix, womb, prostate, eye and skin, and less often for cancers of the breast, head and neck, oesophagus and lung. It can be used alone or as a “boost” after a course of external beam radiotherapy.

The main types

Type How it works Typical examples
High dose rate (HDR) A single powerful source is passed into thin tubes for a few minutes, then removed Cervix, womb, prostate, skin
Low dose rate (LDR), permanent seeds Tiny radioactive seeds are left in the organ and slowly lose their activity over months Prostate
Pulsed dose rate (PDR) A source moves in and out in short pulses over a day or two Some gynaecological and other cancers
Eye plaque A small disc with radioactive material is stitched to the outside of the eye for a few days Uveal melanoma, retinoblastoma

1. Key facts at a glance

Feature Details
Type of treatment Internal radiotherapy
Main uses Cervical, endometrial, prostate and eye cancers
How it is given Radioactive source placed in a body cavity, in tubes or needles in the tissue, or as permanent seeds
Anaesthetic Often general or spinal; some treatments need none
Course length From a single session to several sessions over 1-3 weeks; seeds are a single procedure
Hospital stay Day case for most HDR treatments; overnight or a few days for some
Radiation safety No radiation remains after HDR; precautions are needed for a short time with permanent seeds

2. How it works

Every form of radiotherapy harms the DNA inside cancer cells. Normal cells can repair this damage better than cancer cells. The special feature of brachytherapy is the steep fall in dose with distance from the source.

Property Effect
Short range Dose drops sharply a few millimetres to centimetres from the source
Moves with the organ Because the source is inside the tumour or cavity, small movements matter less
High local dose Allows doses higher than external beams can safely reach
Image guidance Ultrasound, CT or MRI shows exactly where the tumour and organs lie

European guidelines for prostate brachytherapy describe how it can raise the dose beyond that possible with external beams alone, with less dose to the rectum, bladder and penile bulb (Henry et al., 2022).

3. Who it is for

Conditions treated

Condition Role of brachytherapy
Cervical cancer Essential part of curative treatment for locally advanced cancer, after chemoradiotherapy
Endometrial cancer Vaginal brachytherapy after surgery to lower the risk of the cancer returning in the vagina
Vaginal cancer Often combined with external radiotherapy
Prostate adenocarcinoma Seeds or HDR alone for lower-risk cancer, or as a boost for higher-risk cancer
Uveal melanoma Eye plaque treatment that often saves the eye
Retinoblastoma Plaque treatment for selected tumours
Basal cell carcinoma Surface applicators for people who cannot have surgery
Oesophageal squamous cell carcinoma Relief of swallowing problems in advanced disease
Oral cavity squamous cell carcinoma Selected small tumours of the lip and tongue at specialist centres

Who may not be suitable

Situation Reason
Very large tumours The dose may not reach all parts of the tumour
Anatomy that prevents placement For example, a narrow vagina or a very large prostate
Unfit for anaesthetic Some techniques require it
Previous treatment to the area May limit the safe dose

4. Before treatment

Step Details
Assessment Examination and scans to decide whether brachytherapy is suitable
Planning visit You may have an MRI, CT or ultrasound in the treatment position
Blood tests and anaesthetic check If an anaesthetic is needed
Bowel preparation Sometimes an enema or diet changes before pelvic treatment
Consent Your team explains the steps, risks and alternatives

5. What to expect: step by step

Gynaecological HDR brachytherapy (for example, cervical cancer)

Step What happens
1. Anaesthetic A spinal or general anaesthetic is given
2. Applicator insertion A hollow applicator is placed in the vagina and womb; thin needles may be added
3. Imaging An MRI or CT scan shows the applicator, tumour and nearby organs
4. Planning Physicists calculate how long the source should stay at each position
5. Treatment You lie still while a machine sends the source through the tubes; staff watch from outside the room
6. Removal The applicator is removed, often after a few minutes of treatment
7. Repeat This is usually repeated 2-4 times over one to two weeks

Prostate seed brachytherapy

Step What happens
1. Anaesthetic General or spinal
2. Ultrasound guidance An ultrasound probe is placed in the back passage
3. Needle placement Needles are passed through the skin between the scrotum and anus
4. Seed placement Around 60-120 tiny seeds are left in the prostate
5. Recovery Most men go home the same day or the next morning
6. Check scan A CT scan about a month later confirms the seed positions

Eye plaque treatment

A plaque is stitched to the white of the eye during a short operation. It stays in place for a few days, usually during a hospital stay, and is removed in a second short operation.

6. Side effects and risks

Side effects depend on the part of the body treated. Most are short-lived, but some can develop months or years later.

Area treated Short-term effects Possible longer-term effects
Cervix and womb Vaginal discharge, mild bleeding, tiredness, bowel or bladder irritation Vaginal narrowing or dryness, bladder or bowel changes, rarely a fistula
Prostate Frequent or urgent passing of urine, slow flow, discomfort Erection problems, urinary symptoms, rectal bleeding
Eye Eye discomfort, redness Cataract, dry eye, radiation damage to the retina or optic nerve, vision loss
Skin Redness and peeling Skin colour changes, thin skin

Numbers from studies

Study Severe late effects reported
EMBRACE-I, cervical cancer Five-year rate of serious effects about 6.8% for urinary problems, 8.5% for bowel problems, 5.7% for vaginal problems and 3.2% for fistula (Potter et al., 2021)

7. Results and outlook

Study Main finding
EMBRACE-I (1341 people with cervical cancer) Chemoradiotherapy followed by MRI-guided brachytherapy gave five-year local control of about 92% (Potter et al., 2021)
PORTEC-2 (427 women with endometrial cancer) Vaginal brachytherapy matched pelvic external radiotherapy for vaginal recurrence and overall survival at 10 years; external radiotherapy gave better pelvic control in women with unfavourable features (Wortman et al., 2018)
ASCENDE-RT (398 men with prostate cancer) A seed brachytherapy boost halved the risk of PSA failure compared with an external beam boost, though overall survival was similar (Morris et al., 2017)

These trials show that brachytherapy is not just an add-on. For cervical cancer especially, it is a core part of treatment that cannot easily be replaced.

Why imaging has changed brachytherapy

In the past, brachytherapy doses were planned using simple X-ray films and fixed reference points. Today, MRI and CT scans taken with the applicator in place show the actual shape of the tumour and the position of the bladder, bowel and rectum. The plan can then be adjusted for each session. This approach, called image-guided adaptive brachytherapy, is a major reason why results for cervical cancer have improved while serious side effects have stayed low.

The prostate trial in context

In ASCENDE-RT, men in both groups also received a year of hormone therapy and radiotherapy to the pelvic lymph nodes. The seed boost gave better PSA control over time, but the trial did not show that men lived longer (Morris et al., 2017).

Seed brachytherapy can also cause more troublesome urinary symptoms in some men than external beam treatment. Because of this trade-off, the choice of boost is made together with each man, taking account of his current urinary symptoms, prostate size and personal preferences.

8. Recovery and aftercare

Recovery timeline

Period What to expect
First few days Mild discomfort and tiredness after the anaesthetic
1-4 weeks Urinary or bowel irritation may peak
1-3 months Most short-term effects settle
3-6 months First check of tumour response
Long term Regular follow-up for late effects

Practical advice

Topic Advice
Vaginal dilators Often recommended after gynaecological treatment to reduce narrowing
Sex Usually possible again after a few weeks; with seeds, a condom may be advised at first
Seeds and close contact Avoid long periods with small children or pregnant women on your lap for a short time, as advised
Urine symptoms Drink plenty of fluids and avoid caffeine; tell your team if you cannot pass urine
Eye care Use eye drops as prescribed and attend regular eye checks

Living with permanent seeds

The seeds lose most of their radioactivity within a few months and then stay in the prostate harmlessly for life. They do not set off most security systems, but carrying your treatment card is sensible. If you need surgery or a cremation in the future, the information on this card helps staff take the right steps.

Emotional support

Brachytherapy to intimate areas can feel embarrassing or distressing. Staff are used to these feelings and aim to protect your privacy and dignity. Ask about relaxation techniques, extra pain relief and psychosexual support if you need them.

Follow-up checks

After treatment you will have regular appointments, often every few months at first and then less often. These may include examinations, PSA blood tests for prostate cancer, eye checks for eye tumours or scans where needed. Tell your team about any new bleeding, pain or changes in bladder or bowel habits between visits.

9. Alternatives

Alternative When it is considered
External beam radiotherapy alone When brachytherapy is not possible; may need higher doses to nearby organs
Stereotactic radiotherapy Sometimes used for prostate cancer and other sites
Surgery For example, prostatectomy or hysterectomy in suitable people
Active surveillance Low-risk prostate cancer
Proton therapy Some eye tumours
Removal of the eye Large uveal melanomas

10. Frequently asked questions

Question Answer
Will I be radioactive? Not after HDR treatment; with seeds, a small amount of radiation is given off for a few months
Does it hurt? Placement is done under anaesthetic or with pain relief; the radiation itself cannot be felt
Can the seeds move? Rarely; a seed may occasionally be passed in urine or semen
Can I travel after seed implants? Yes; carry the card your team provides in case airport detectors are triggered
Will I need external radiotherapy too? Often, depending on the cancer and its stage
How many treatments will I need? From one to several, depending on the type of brachytherapy

11. Questions to ask your care team

  • What type of brachytherapy do you recommend, and why?
  • How many sessions will I need?
  • Will I need an anaesthetic?
  • What short-term and long-term side effects should I expect?
  • Are there any radiation precautions for my family?
  • How will this affect my sex life and fertility?
  • When will I know if the treatment has worked?

Resources

  1. Henry, A. et al. (2022) ‘GEC-ESTRO ACROP prostate brachytherapy guidelines’, Radiotherapy and Oncology, 167, pp. 244-251.
  2. Morris, W.J. et al. (2017) ‘Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer’, International Journal of Radiation Oncology, Biology, Physics, 98(2), pp. 275-285.
  3. Potter, R. et al. (2021) ‘MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study’, The Lancet Oncology, 22(4), pp. 538-547.
  4. Wortman, B.G. et al. (2018) ‘Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy’, British Journal of Cancer, 119(9), pp. 1067-1074.
  5. National Cancer Institute (2026) Brachytherapy for Cancer. Available at: https://www.cancer.gov/about-cancer/treatment/types/radiation-therapy/brachytherapy (Accessed: October 2026).

Prepared by the editorial team, October 2026.